Page 79 - 《中国药房》2022年10期

·药物经济学·

基于中国人群的糖尿病治疗药物经济学评价文献的系统评估和

质量评价 Δ

1＊
1
2
罗 琼 ，周 黎 ，冯海欢 ，胡 明 （1.四川大学华西药学院，成都 610041；2.四川大学华西医院医保办，
1 #
成都 610041）
中图分类号 R956 文献标志码 A 文章编号 1001-0408（2022）10-1225-08
DOI 10.6039/j.issn.1001-0408.2022.10.12

摘 要 目的 系统回顾基于中国人群糖尿病治疗药物的经济学研究，为促进我国糖尿病领域药物经济学研究的开展和研究质量
的提升提供参考。方法 检索PubMed、Embase、中国生物医学文献服务系统、中国知网、万方数据和维普网等数据库，收集基于中
国人群的糖尿病治疗药物经济学评价文献，对文献的发表情况、研究内容、研究设计等进行分析，并使用“卫生经济学评价报告标
准共识 2013（CHEERS 2013）清单”对文献报告质量进行评价。结果 共纳入相关文献 380 篇，包括中文文献 348 篇、英文文献 32
篇。首篇基于中国人群的糖尿病治疗药物的经济学评价文献于2001年发表；评价最多的药物为二甲双胍；大部分研究由医疗机
构开展（79.2％），多为短期经济性评价（73.9％）、方法主要为成本-效果分析（61.8％），且大部分未报告明确的研究角度（82.6％）。
经CHEERS 2013清单评价，纳入文献的平均得分为10.57分，85.8％的文献报告质量不合格。中文文献的平均得分为10.05分，英
文文献的平均得分为16.23分，英文文献的报告质量明显优于中文文献（P＜0.001）。结论 现有的基于中国人群的糖尿病治疗药物
经济学评价文献研究质量较低，存在研究角度缺失、研究机构/方法单一、报告不规范等问题。建议医疗机构、高校/研究院、企业和
政府部门等机构加强合作，提高研究水平，并关注更多、更新的临床有效治疗方案，促进研究结果的证据转化。
关键词 中国人群；糖尿病；治疗药物；药物经济学；文献计量学分析；质量评价
Systematic assessment and quality evaluation of literatures on economic evaluation of diabetes drugs in
Chinese population
LUO Qiong ，ZHOU Li ，FENG Haihuan ，HU Ming（1. West China School of Pharmacy，Sichuan University，
2
1
1
1
Chengdu 610041，China；2. Medical Insurance Office，West China Hospital of Sichuan University，Chengdu
610041，China）
ABSTRACT OBJECTIVE To review economic studies of diabetes drugs in Chinese population systematically，and to provide
reference for promoting the development of pharmacoeconomics research in the field of diabetes and improving the research quality.
METHODS Retrieving from PubMed，Embase，SinoMed，CNKI，Wanfang data，VIP and other databases，the literatures on
economic evaluation of diabetes drugs in Chinese population were collected；analysis was carried out on the publication，research
content，study design of the literatures. The Consolidated Health Economic Evaluation Reporting Standards 2013（CHEERS 2013）
checklist was used for quality evaluation. RESULTS A total of 380 literatures were included，involving 348 Chinese literatures and
32 English literatures. The first paper of diabetes drugs in Chinese population was published in 2001. The most evaluated drug was
metformin. Most of the studies（79.2％）were conducted by medical institutions，73.9％ of the studies were short-term economic
evaluation，and the methods were mainly cost-effectiveness analysis （61.8％），and most of the studies did not reported clear
research perspectives（82.6％）. Evaluated by CHEERS 2013，the average score of included literatures was only 10.57，and 85.8％
of the literatures was of unqualified quality. The average score of Chinese literatures was 10.05，that of English literatures was
16.23， and the reporting quality of English literatures was significantly better than that of Chinese literatures（P＜0.001）.
CONCLUSIONS The existing literatures on the economic evaluation of diabetes drugs in Chinese population is of low quality.
There are problems such as lack of research perspectives，single research institution/method，and non-standard reporting. It is
recommended that medical institutions，universities/research institutions，enterprises，government and other institutions should
strengthen cooperation，improve their research level，pay attention to more and newer clinically effective treatment regimens，and
promote the transformation of research results into decision-making evidence.
KEYWORDS Chinese population；diabetes；therapeutic drugs；pharmacoeconomics；bibliometric analysis；quality evaluation

Δ 基金项目：四川省科技计划项目（No.2021YFS0145）
糖尿病是一种慢性代谢性疾病，其发病率和死亡
＊硕士研究生。研究方向：药物政策与药物经济学。E-mail：
[1]
率在全球范围内呈逐年上升趋势 。国际糖尿病联盟
1621053055@qq.com
# 通信作者：教授，硕士生导师，博士。研究方向：药物政策与药 （International Diabetes Federation，IDF）统计数据显示，
物经济学。E-mail：huming@scu.edu.cn 2019 年全球共有 4.63 亿 20～79 岁的糖尿病成人患者，

中国药房 2022年第33卷第10期 China Pharmacy 2022 Vol. 33 No. 10 ·1225 ·